Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · Real-Time Price · USD
2.090
-0.080 (-3.69%)
Aug 26, 2026, 10:22 AM EDT - Market open
Allogene Therapeutics Stock Forecast
Stock Price Forecast
According to 12 analysts polled by S&P Global, Allogene Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $9.00. The average 1-year stock price forecast is 330.62% higher than the current stock price, while the lowest is $4.00 (+91.39%) and the highest is $14 (+569.86%).
Price Target: $9.00 (+330.62%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Allogene Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 10 | 9 | 8 | 8 | 8 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 1 | 2 | 2 | 2 | 1 | 1 |
| Sell | 1 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15 | 15 | 14 | 13 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| J.P. Morgan | J.P. Morgan | Hold Maintains n/a | Hold | Maintains | n/a | n/a | Aug 17, 2026 |
| TD Cowen | TD Cowen | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Aug 13, 2026 |
Unknown Analyst UBS No rating | UBS | Buy Reiterates $8 | Buy | Reiterates | $8 | +282.78% | Aug 13, 2026 |
| RBC Capital | RBC Capital | Buy Reiterates $9 | Buy | Reiterates | $9 | +330.62% | Aug 13, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $10 | Buy | Maintains | $10 | +378.47% | Aug 13, 2026 |
Financial Forecast
Revenue This Year
3.40M
Revenue Next Year
12.09M
from 3.40M
Increased by 255.46%
EPS This Year
-0.59
from -0.85
EPS Next Year
-0.70
from -0.59
EPS and Forward PE are based on non-GAAP adjusted numbers.